The University Hospitals of North Midlands NHS Trust (UHNM) has been recognized for its significant contribution to stroke research, having recruited nearly 300 stroke patients for the ATTEST 2 and OPTIMAS trials between 2017 and 2024. These trials have been pivotal in advancing stroke treatment methodologies.
The ATTEST 2 trial focused on evaluating the efficacy of tenecteplase, a new clot-busting medication that offers practical advantages over the current standard, alteplase, including the possibility of administration via a single injection. This could significantly streamline the treatment process for ischemic stroke patients, potentially allowing for quicker intervention.
The OPTIMAS trial explored the benefits of initiating blood-thinning treatments earlier for stroke patients with atrial fibrillation (AF), a heart rhythm disturbance. Contrary to previous recommendations of waiting up to 14 days post-stroke to start anticoagulants due to fears of brain bleeding, the trial found that beginning treatment within four days is both safe and effective, without increasing the risk of brain hemorrhage, even in patients with more severe strokes.
Dr. Mohammed Shoaib, associate principal investigator, highlighted the importance of these trials in addressing critical gaps in stroke medicine, potentially influencing international treatment practices. The success of these trials is a testament to the dedication of the UHNM Research and Innovation teams, who managed to continue patient recruitment even during the challenging times of the Covid-19 pandemic.
Resti Varquez, a senior research practitioner at UHNM, expressed pride in the team's efforts and the positive impact of the trial results on stroke patient recovery times. Despite the challenges posed by the pandemic, including staffing pressures and infection risks, the team persevered, ensuring the trials' success and the advancement of stroke treatment options.
